Business News | Stock and Share Market News | Finance News

Late-stage clinical trials showed Paxlovid cut hospitalisation and death risks in mild to moderately high-risk COVID-19 patients by up to 88 percent and new evidence is emerging that it is also dramatically effective in treating long COVID symptoms.

No end in sight for India’s wait for Paxlovid, the most promising COVID-19 drug yet, despite surging cases

Name Price Change % Chg
Nhpc 34.90 1.20 3.56
Ntpc 160.50 -0.15 -0.09
Sbi 509.30 -2.50 -0.49
Indiabulls Hsg 158.35 1.20 0.76




Which of these youngsters will score more runs this ipl?


Thank You for Voting